	Tick all that apply
Head & Neck (H&N)	no
Central nervous system (CNS)	no
Skin/ Melanoma	yes
Urology/ Renal	yes
Gynae-Onc	yes
Breast	yes
Upper Gastrointestinal (UGI)	yes
Lower Gastrointestinal (LGI)	yes
Hepato-pancreatico-biliary (HPB)	yes
Cancer of unknown primary (CUP) Lung	no
Sarcoma	no
None of the above (ensure you do not tick any other	
boxes)	

<sup>\* 1.</sup>Ic In TOTAL, how many dinical trials (interventional Phase 0 - III) involving novel or novel combination or novel way of administering systemic anti-cancer therapies for solid cancers did you have in the Oncology department on 31 D

2014	9
2015	5
2016	6
2017	5
2018	4
2019	5
2020	5
2021	5
2022	4
2023	3

<sup>\* 1.</sup>lh On a separate note, how many Phase IV trials did you conduct in each year at your hospital/  $Trq7.96\ T/F2\ 9.96\ Tf1\ 1\ 0\ 0.580.39\ Tm0\ f^*\ 128.54\ 706.42\ 0.48\ 12(1\ 0\ 0\ 1\ 72.024\ 580.39\ Tm0\ 2\ 0.[T)5/F2\ 9.96\ Tf1\ 0\ 0\ 1\ 123.38\ 592.$ 

 $^{*}$  1.lj Provide the total number of adult patients enrolled in phase I - III solid-cancer systemic anticancer therapy trials on 31 Dec of each year at your hospital/ Trust:

	Number of trials, n
2010	
2011	
2012	
2013	
2014	
2015	
2016	
2017	
2018	
2019	
2020	
2021	
2022	
2023	

\* 1.lk In each year, how many new Phase I - III dinical trials did you open for recruitment?

	Number of trials, n
2010	6
2011	3
2012	2
2013	1
2014	2
2015	2
2016	4
2017	2
2018	1
2019	1
2020	1
2021	0
2022	0
2023	0

* trials at	2.I Post-BREXIT, what regulatory changes have had the greatest impact on the initiation of oncology your centre?
* of onco	2.II Post-BREXIT, what regulatory changes have had the greatest impact on the conduct/ continuation logy trials at your centre?

\* 2.IIIa Post-initiating new oncology trials at your centre?


	Tick one
Yes	
No	
Unsure	

\* 2.IIIb If yes, please specify the regulatory challenges encountered:

\*

\* 2.VIa Have there been any new documentation or compliance requirements introduced post-BREXIT for ongoing oncology trials?

	Tick one
Yes	
No	
Unsure	



\* 2.VIIIa Have there been any changes in the requirements for informed consent processes for oncology trials post-BREXIT?

Tick one

regulatory changes post-BREXIT?

* 2.>	2.Xb If yes, explain how:	
* 2.>	2.Xc If no, explain why not:	
* 21	3.I In each year, how many Phase 0 - IV clinical trials did you have to d	liccontinuo duo to a lade of
3.1	5.1 III each year, now mainy mase 0 - 17 chinical thais did you have to d	iiscontinue due to a lack of
	Number of trials, n	
2010	Trainist of trials, it	
2011		
2012		
2013		
2014		
2015		
2016		
2017		
2018		
2019		
2020		
2021		
2022		
2023		
* 3.1	3.II Name all organisations, including your own, that sponsored and/o	r funded solid- cancer systemic-
anticancer t	er therapy trials at your centre in each year:	
	Sponsors/ funders	
2010		
2011		
2012		
2013		
2014		

	2015			
	2016			
	2017			
	2018			
	2019			
	2020			
	2021			
·	2022			

* - initiated trials, certain types of systemic anti-cancer drugs, combination therapies, for certain tumour groups)?	
*	

	Tick one
Yes	
No	
Unsure	

* 3.)	If yes, please elaborate on the key changes in criteria or preferences:	
* 4.I running of s	d-cancer systemic anti- cancer therapy drugs:	
	Collaborative Challenges	
2010		
2011		
2012		
2013		
2014		
2015		
2016		
2017		
2018		
2019		_
2020		
2022		
2023		_
* 4.I BREXIT?	Have there been challenges in maintaining international collaborations for onc	ology trials post-
\/aa	īck one	
Yes No		
Unsure	<del></del>	
	f yes, please identify the main collaborative challenges faced:	
* 4.1	Have changes in regulatory requirements impacted international partnerships	in oncology trials?
	īck one	

Yes	
No	
Unsure	

\* 4.IIIb

oncology trials?

	Tick one
Yes	
No	
Unsure	

\* 4.VIIa patient populations across international sites in oncology trials?

Tick one